Wall Street Zen downgraded shares of Lite Strategy (NASDAQ:LITS – Free Report) from a hold rating to a strong sell rating in a research note released on Saturday,Wall Street Zen reports.
Separately, Weiss Ratings upgraded Lite Strategy from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, October 26th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, Lite Strategy has an average rating of “Sell”.
View Our Latest Research Report on Lite Strategy
Lite Strategy Trading Down 4.6%
Lite Strategy (NASDAQ:LITS – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The company reported $0.48 EPS for the quarter.
Hedge Funds Weigh In On Lite Strategy
Several institutional investors and hedge funds have recently bought and sold shares of LITS. ADAR1 Capital Management LLC purchased a new stake in shares of Lite Strategy in the 2nd quarter valued at approximately $62,000. BlackRock Inc. acquired a new position in Lite Strategy during the 2nd quarter worth about $254,000. GSA Capital Partners LLP acquired a new position in Lite Strategy during the 2nd quarter worth about $57,000. Finally, Renaissance Technologies LLC lifted its stake in Lite Strategy by 13.2% during the 1st quarter. Renaissance Technologies LLC now owns 1,744,700 shares of the company’s stock worth $2,024,000 after acquiring an additional 203,278 shares in the last quarter. 52.38% of the stock is currently owned by institutional investors and hedge funds.
Lite Strategy Company Profile
Lite Strategy, Inc. is a digital-asset treasury company focused on acquiring and holding Litecoin as a primary reserve asset. Its business centers on managing this Litecoin-focused strategy rather than providing consumer products or services. The company was formerly known as MEI Pharma, a clinical-stage biopharmaceutical company that worked on treatments for cancer. It later shifted its business focus to a Litecoin treasury strategy. Lite Strategy’s activities therefore primarily involve its digital-asset holdings and related treasury management; the company is not principally engaged in drug development under its current strategy.
See Also
- Five stocks we like better than Lite Strategy
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Lite Strategy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lite Strategy and related companies with MarketBeat.com's FREE daily email newsletter.
